(Q36217132)

12 August 2017

1 reference

title

Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? (English)

1 reference

12 August 2017

0 references

1 reference

Peter C Albertsen

1

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

44

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

255-264

1 reference

12 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Results of conservative management of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Age-specific reference ranges for serum prostate-specific antigen in black men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Early prostate cancer: clinical decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Periprostatic local anesthesia before ultrasound-guided prostate biopsy: an update of the miami experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Screening of infants and mortality due to neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

Screening for prostate cancer: recommendation and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410002815

10.1080/02841860410002815

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference